GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Total Stockholders Equity

CG Oncology (CG Oncology) Total Stockholders Equity : $568.94 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Total Stockholders Equity?

CG Oncology's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $568.94 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. CG Oncology's Book Value per Share for the quarter that ended in Mar. 2024 was $8.54. The ratio of a company's debt over equity can be used to measure how leveraged this company is. CG Oncology's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.00.

CG Oncology Total Stockholders Equity Historical Data

The historical data trend for CG Oncology's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Total Stockholders Equity Chart

CG Oncology Annual Data
Trend Dec21 Dec22 Dec23
Total Stockholders Equity
-42.62 125.18 184.79

CG Oncology Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Total Stockholders Equity Get a 7-Day Free Trial 125.18 - -108.02 184.79 568.94

CG Oncology  (NAS:CGON) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

CG Oncology's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(568.94-0)/66.6363
=8.54

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

CG Oncology's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.22 + 0.184) / 568.94
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CG Oncology Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of CG Oncology's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology (CG Oncology) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Total Stockholders Equity
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024